Iran Acquires Knowledge to Produce Urea Lowering Drug for Cancer Patients

Cancer patients undergoing chemotherapy face the complication of increased urea, which must be quickly reduced in the body.

The company started operation in 2019 with the aim of producing and developing technical know-how of high-tech drugs in the field of biotechnology and human and animal supplements.

The main goal of the company is the production of advanced biotechnology drugs that have a foreign-made sample.

Normally, uric acid is dissolved in the blood and excreted from the body through the kidneys and urine, and if the production of uric acid increases or its excretion from the kidneys decreases, the amount of uric acid in the blood increases, which leads to hyperuricemia.

The newly-produced medicine is used to treat hyperuricemia in cancer patients undergoing chemotherapy.

Rasburicase is used to treat high levels of uric acid in the blood of adults and children with leukemia, lymphoma, or other types of cancer who are receiving certain types of anticancer therapy.

Uric acid is a natural substance that can build up in the blood as tumors break down.

Rasburicase helps break down and remove uric acid from the body. It is a type of recombinant enzyme and a type of urate-lowering drug.

Genetic factors, hypothyroidism, taking drugs that weaken the immune system, widespread infection, obesity, leukemia, lymphoma, and radiation therapy are among the factors that increase uric acid in the body.

4155/g